Table 1 Baseline clinical characteristics of DCM patients with and without T2DM

Male, n

786 (68%)

115 (74%)

671 (67%)

0.09

Age (years)

48 ± 14

55 ± 12

47 ± 14

< 0.001

BMI (kg/m²)

24.0 ± 4.1

24.5 ± 3.9

23.9 ± 4.1

0.07

SBP (mmHg)

116 ± 17

116 ± 19

115 ± 17

0.73

DBP (mmHg)

76 ± 13

76 ± 14

76 ± 13

0.88

NYHA class, n

0.003

 I

137 (12%)

7 (5%)

130 (13%)

 II

451 (39%)

55 (36%)

396 (40%)

 III

420 (37%)

72 (47%)

348 (35%)

 IV

144 (13%)

21 (14%)

123 (12%)

Hypertension, n

266 (23%)

57 (37%)

209 (21%)

< 0.001

Atrial fibrillation, n

207 (18%)

48 (31%)

159 (16%)

< 0.001

LBBB, n

130 (11%)

17 (11%)

113 (11%)

0.89

Smoking, n

473 (41%)

75 (48%)

398 (40%)

0.05

Alcohol, n

318 (28%)

49 (32%)

269 (27%)

0.23

ACEI/ARB/ARNI, n

943 (82%)

133 (86%)

810 (81%)

0.17

β-blockers, n

950 (83%)

131 (85%)

819 (82%)

0.47

MRA, n

841 (73%)

121 (78%)

720 (72%)

0.13

Diuretics, n

785 (68%)

118 (76%)

667 (67%)

0.02

Digoxin, n

250 (22%)

45 (29%)

205 (21%)

0.02

Anticoagulants, n

164 (14%)

42 (27%)

122 (12%)

< 0.001

SGLT2i, n

89 (8%)

37 (24%)

52 (5%)

< 0.001

Biguanides, n

54 (5%)

54 (35%)

0

-

a-Glucosidase inhibitor, n

37 (3%)

37 (24%)

0

-

Insulin, n

29 (3%)

29 (19%)

0

-